Chemistry:Futuximab
From HandWiki
Short description: Monoclonal antibody
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | HER1 |
Clinical data | |
Other names | 992 DS |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6468H10002N1724O2055S46 |
Molar mass | 146269.94 g·mol−1 |
Futuximab (992 DS) (INN) is a chimeric monoclonal antibody designed for the treatment of cancer.[1] It acts as an immunomodulator and also binds to HER1.[2][3]
This drug was developed by Symphogen.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab, American Medical Association.
- ↑ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107". WHO Drug Information 26 (2). https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf.
- ↑ "Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models". J. Neurooncol. 138 (3): 489–498. July 2018. doi:10.1007/s11060-018-2832-6. PMID 29564747.
Original source: https://en.wikipedia.org/wiki/Futuximab.
Read more |